Literature DB >> 2513865

In situ hybridization detection of light chain mRNA in routine bone marrow trephines from patients with suspected myeloma.

N Akhtar1, A Ruprai, J H Pringle, I Lauder, S T Durrant.   

Abstract

A method for the detection of immunoglobulin light chain mRNA by situ hybridization has been applied to routine bone marrow trephines, from patients suspected of having multiple myeloma. The principle aim was to define monoclonal populations even in cases lacking a paraprotein or an obvious atypical plasma cell proliferation. The expression of light chain mRNA in plasma cells in routine bone marrow trephines from 14 patients with suspected myeloma was studied. Plasma cells in the marrow ranged from 4% to 99%. Clonal populations based on light chain restriction were delineated in 12 patients, using biotinylated probes to kappa and lambda mRNA and visualized using an alkaline phosphatase/fast red naphthol capture method. Normal tonsil and bone marrow trephines were used as controls. In situ hybridization was found to be a specific, safe and rapid technique. It could be applied to both fixed and fresh tissue. It was found to lack the background staining of interstitial immunoglobulin, particularly in sclerotic cases, which is so often encountered with immunocytochemistry. Additionally, this technique will type plasma cell neoplasms (undetected by routine immunocytochemistry) in post-transcriptional block or non-secretory myeloma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513865     DOI: 10.1111/j.1365-2141.1989.tb07743.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  In situ hybridisation in perspective.

Authors:  A Warford; I Lauder
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

2.  Detection of immunoglobulin light-chain mRNA in lymphoid tissues using a practical in situ hybridization method.

Authors:  L M Weiss; L A Movahed; Y Y Chen; S S Shin; R M Stroup; N Bui; P Estess; J M Bindl
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

3.  Model system for optimising mRNA non-isotopic in situ hybridisation: riboprobe detection of lysozyme mRNA in archival gut biopsy specimens.

Authors:  J C Martinez-Montero; C S Herrington; J Stickland; H Sawyer; M Evans; D M Flannery; J O McGee
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

4.  Comparison of in situ hybridisation and polymerase chain reaction in the diagnosis of B cell lymphoma.

Authors:  A M McNicol; M A Farquharson; F D Lee; A K Foulis
Journal:  J Clin Pathol       Date:  1998-03       Impact factor: 3.411

5.  Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA.

Authors:  S J Harper; A C Allen; J H Pringle; J Feehally
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

6.  Immunoglobulin light chain mRNA detected by in situ hybridisation in diagnostic fine needle aspiration cytology specimens.

Authors:  C J Stewart; M A Farquharson; T Kerr; J McCorriston
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

Review 7.  Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.

Authors:  K N Naresh; I Lampert; R Hasserjian; D Lykidis; K Elderfield; D Horncastle; N Smith; W Murray-Brown; G W Stamp
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

Review 8.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

9.  Sites of M-CSF messenger RNA production in bone marrow trephine biopsy specimens and long term cultures demonstrated by nonisotopic in situ hybridisation.

Authors:  B S Wilkins; D B Jones
Journal:  Clin Mol Pathol       Date:  1995-02

10.  EBER oligonucleotide RNA in situ hybridization in EBV associated neoplasms.

Authors:  T Tornóczky; G Kelényi; L Pajor
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.